Sean P David

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4752003/publications.pdf

Version: 2024-02-01

78 papers

5,233 citations 126858 33 h-index 98753 67 g-index

83 all docs 83 docs citations

83 times ranked 8898 citing authors

#	Article	IF	CITATIONS
1	Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. Journal of Personalized Medicine, 2022, 12, 1145.	1.1	1
2	Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System. Journal of the American Board of Family Medicine, 2021, 34, 861-865.	0.8	20
3	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. The Cochrane Library, 2021, 2021, CD011823.	1.5	O
4	The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System. Journal of Personalized Medicine, 2021, 11, 1242.	1.1	4
5	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	4.1	83
6	Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?. Nicotine and Tobacco Research, 2019, 21, 1289-1293.	1.4	5
7	Tobacco Genomics: Complexity and Translational Challenges. Nicotine and Tobacco Research, 2019, 21, 705-706.	1.4	2
8	Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nature Genetics, 2019, 51, 237-244.	9.4	1,307
9	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and AlcoholÂUse. Biological Psychiatry, 2019, 85, 946-955.	0.7	69
10	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. The Cochrane Library, 2018, 2018, CD011823.	1.5	28
11	Potential Reporting Bias in Neuroimaging Studies of Sex Differences. Scientific Reports, 2018, 8, 6082.	1.6	109
12	Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach. Journal of Community Genetics, 2018, 9, 283-291.	0.5	17
13	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. Nicotine and Tobacco Research, 2018, 20, 403-413.	1.4	16
14	Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. Nicotine and Tobacco Research, 2018, 20, 414-424.	1.4	15
15	From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics, 2018, 19, 861-871.	0.6	16
16	Clinical and Personal Utility of Genetic Risk Testing. American Family Physician, 2018, 97, 600-602.	0.1	1
17	Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction, 2017, 112, 1451-1459.	1.7	19
18	Novel Methodologies and the Need for Big Data in Nicotine and Tobacco Genetics Research. Nicotine and Tobacco Research, 2017, 19, 385-386.	1.4	1

#	Article	IF	CITATIONS
19	Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Molecular Carcinogenesis, 2016, 55, 1424-1437.	1.3	4
20	Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence. BMJ Open, 2016, 6, e010960.	0.8	8
21	Gene by Environment Interaction Linking the Chromosome 15q25 Locus with Cigarette Consumption and Lung Cancer Susceptibility - Are African American Affected Differently? — Authors' Reply. EBioMedicine, 2016, 4, 15.	2.7	0
22	Gene by Environment Investigation of Incident Lung Cancer Risk in African-Americans. EBioMedicine, 2016, 4, 153-161.	2.7	12
23	Teaching Medical Students to Help Patients Quit Smoking: Outcomes of a 10-School Randomized Controlled Trial. Journal of General Internal Medicine, 2016, 31, 172-181.	1.3	34
24	Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. Nicotine and Tobacco Research, 2015, 17, 855-861.	1.4	3
25	Medical school curriculum characteristics associated with intentions and frequency of tobacco dependence treatment among 3rd year U.S. medical students. Preventive Medicine, 2015, 72, 56-63.	1.6	14
26	Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable. Annals of Family Medicine, 2015, 13, 373-380.	0.9	34
27	Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. Journal of the American Academy of Dermatology, 2015, 72, 190-191.e3.	0.6	14
28	Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open, 2014, 4, e004393.	0.8	26
29	Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Human Brain Mapping, 2014, 35, 3052-3065.	1.9	50
30	No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. Menopause, 2014, 21, 415-420.	0.8	5
31	Commentary on <scp>C</scp> hen <i>et al</i> . (2014): Another step on the road to clinical utility of pharmacogenetics for smoking cessation?. Addiction, 2014, 109, 138-139.	1.7	3
32	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398
33	Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. Trends in Cognitive Sciences, 2014, 18, 235-241.	4.0	361
34	Effects of Nicotine Deprivation and Replacement on BOLD-fMRI Response to Smoking Cues as a Function of DRD4 VNTR Genotype. Nicotine and Tobacco Research, 2014, 16, 939-947.	1.4	11
35	Teaching tobacco dependence treatment and counseling skills during medical school: Rationale and design of the Medical Students helping patients Quit tobacco (MSQuit) group randomized controlled trial. Contemporary Clinical Trials, 2014, 37, 284-293.	0.8	18
36	Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction, 2013, 108, 2202-2211.	1.7	30

#	Article	IF	Citations
37	Tobacco dependence treatment teaching by medical school clerkship preceptors: Survey responses from more than 1000 US medical students. Preventive Medicine, 2013, 57, 81-86.	1.6	12
38	Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study. Nicotine and Tobacco Research, 2013, 15, 518-526.	1.4	16
39	Opioid antagonists for smoking cessation. The Cochrane Library, 2013, , CD003086.	1.5	62
40	Potential Reporting Bias in fMRI Studies of the Brain. PLoS ONE, 2013, 8, e70104.	1.1	110
41	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 695-708.	0.7	114
42	Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug and Alcohol Dependence, 2012, 120, 7-13.	1.6	45
43	Smoking and Genetic Risk Variation Across Populations of <scp>E</scp> uropean, <scp>A</scp> sian, and <scp>A</scp> frican <scp>A</scp> merican Ancestryâ€"A Metaâ€Analysis of Chromosome 15q25. Genetic Epidemiology, 2012, 36, 340-351.	0.6	69
44	Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers. Annals of Behavioral Medicine, 2012, 43, 253-261.	1.7	11
45	Chronic psychosocial stressors and salivary biomarkers in emerging adults. Psychoneuroendocrinology, 2012, 37, 1158-1170.	1.3	10
46	The neuroeconomics of nicotine dependence: A preliminary functional magnetic resonance imaging study of delay discounting of monetary and cigarette rewards in smokers. Psychiatry Research - Neuroimaging, 2012, 202, 20-29.	0.9	58
47	Associations of <i>CYP2A6</i> genotype with smoking behaviors in southern China. Addiction, 2011, 106, 985-994.	1.7	46
48	Pharmacogenetics of Smoking Cessation in General Practice: Results From the Patch II and Patch in Practice Trials. Nicotine and Tobacco Research, 2011, 13, 157-167.	1.4	24
49	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. PLoS Genetics, 2011, 7, e1002280.	1.5	137
50	Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. European Journal of Endocrinology, 2011, 165, 961-967.	1.9	29
51	Application of Functional Neuroimaging to Examination of Nicotine Dependence. , 2011, , 117-145.		3
52	Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics, 2010, 11, 357-367.	0.6	47
53	Effects of nicotine withdrawal on verbal working memory and associated brain response. Psychiatry Research - Neuroimaging, 2010, 183, 69-74.	0.9	40
54	Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans. Nicotine and Tobacco Research, 2010, 12, 251-262.	1.4	22

#	Article	IF	CITATIONS
55	Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. Nicotine and Tobacco Research, 2009, 11, 64-76.	1.4	86
56	Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: New data from the Patch in Practice trial and pooled analyses. Drug and Alcohol Dependence, 2008, 98, 77-85.	1.6	27
57	Smoking cessation. BMJ: British Medical Journal, 2008, 336, 217-217.	2.4	2
58	Smoking cessation in primary care. BMJ: British Medical Journal, 2008, 336, 1200-1201.	2.4	3
59	Molecular Genetics of Successful Smoking Cessation. Archives of General Psychiatry, 2008, 65, 683.	13.8	227
60	Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: A diffusion tensor imaging study. Nicotine and Tobacco Research, 2008, 10, 137-147.	1.4	111
61	A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine and Tobacco Research, 2008, 10, 231-240.	1.4	34
62	Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics, 2008, 9, 1307-1321.	0.6	33
63	Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical Trials. Nicotine and Tobacco Research, 2007, 9, 1251-1257.	1.4	74
64	The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine and Tobacco Research, 2007, 9, 225-231.	1.4	56
65	Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1065-1069.	1.1	58
66	Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine and Tobacco Research, 2007, 9, 821-833.	1.4	89
67	SUCCESSFUL LATINO COMMUNITY PARTNERSHIP PROGRAM FOR SMOKING CESSATION. American Journal of Public Health, 2007, 97, 1348-1349.	1.5	1
68	Effects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study. Brain Imaging and Behavior, 2007, 1, 43-57.	1.1	89
69	Opioid antagonists for smoking cessation. , 2006, , CD003086.		41
70	A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT1A Receptor Binding in Humans. Journal of Neuroscience, 2005, 25, 2586-2590.	1.7	253
71	Ventral Striatum/Nucleus Accumbens Activation to Smoking-Related Pictorial Cues in Smokers and Nonsmokers: A Functional Magnetic Resonance Imaging Study. Biological Psychiatry, 2005, 58, 488-494.	0.7	259
72	Does providing hereditary breast cancer risk assessment support to practicing physicians decrease the likelihood of them discussing such risk with their patients?. Genetics in Medicine, 2004, 6, 542-542.	1,1	1

#	Article	IF	CITATION
73	Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine and Tobacco Research, 2004, 6, 769-776.	1.4	59
74	Investigating subgroups in smoking cessation treatment response: Response to Perkins. Nicotine and Tobacco Research, 2004, 6, 865-867.	1.4	9
75	Pharmacogenetics. Primary Care - Clinics in Office Practice, 2004, 31, 543-559.	0.7	6
76	Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?. Nicotine and Tobacco Research, 2003, 5, 935-942.	1.4	53
77	LetterComment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". Nicotine and Tobacco Research, 2003, 5, 397-399.	1.4	18
78	No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics and Genomics, 2002, 12, 265-268.	5.7	48